MedPath

FDA Proposes Ban on Oral Phenylephrine Due to Ineffectiveness as Decongestant

• The FDA is proposing to remove oral phenylephrine from over-the-counter cold medications due to its ineffectiveness as a nasal decongestant. • The decision follows a review of scientific data, including older determinations and recent research, indicating a lack of efficacy. • The FDA emphasizes that the proposed ban is based on ineffectiveness, not safety concerns, regarding oral phenylephrine. • Consumers are advised to seek guidance from healthcare professionals on effective treatments for cold and allergy symptoms.

The Food and Drug Administration (FDA) has proposed a ban on oral phenylephrine, a common ingredient in many over-the-counter cold medications, after determining it is ineffective as a nasal decongestant. This decision follows a comprehensive review of scientific data spanning several decades.
The FDA's evaluation included the original determination made 30 years ago, as well as more recent research. An advisory committee also weighed in, concluding that there was insufficient evidence to support the efficacy of oral phenylephrine in relieving nasal congestion. The agency highlighted that the proposed ban is solely based on the drug's lack of effectiveness and not on any safety concerns.
While the removal of oral phenylephrine might limit options for consumers seeking over-the-counter relief from cold symptoms, the FDA has emphasized the availability of alternative treatments. Individuals experiencing cold and allergy symptoms are encouraged to consult with healthcare professionals to explore other safe and effective medications and remedies to alleviate congestion.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Moves to Remove Oral Phenylephrine as Decongestant Due to Ineffectiveness

The FDA is moving to phase out oral phenylephrine, a common decongestant in over-the-counter cold medicines, after determining it is no more effective than a placebo.
This decision follows expert reviews of studies dating back to the 1960s, which revealed flaws and questionable data regarding phenylephrine's efficacy in oral form.

FDA Proposes Removal of Oral Phenylephrine from OTC Nasal Decongestants

The FDA is proposing to remove oral phenylephrine from over-the-counter nasal decongestants due to its ineffectiveness.
This decision follows a comprehensive review of clinical data and a unanimous recommendation from the Nonprescription Drug Advisory Committee.

FDA Proposes Ban on Oral Phenylephrine in OTC Cold Medications Due to Ineffectiveness

The FDA is proposing to remove oral phenylephrine, a common decongestant, from over-the-counter medications due to its lack of proven effectiveness.
Phenylephrine has been used since 1976 and became more prevalent after pseudoephedrine was moved behind pharmacy counters.

FDA Weighs Removal of Oral Phenylephrine; Approves Drugs for CML, Gastric Cancer, and UTIs

The FDA is considering removing oral phenylephrine from its OTC Monograph due to a lack of efficacy as a nasal decongestant, potentially impacting numerous cold and allergy products.
Novartis' Scemblix expands its FDA-approved uses to include the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ PML).

FDA Proposes Ban on Oral Phenylephrine for Ineffective Nasal Decongestion Relief

The FDA is proposing to ban oral phenylephrine, a common ingredient in OTC cold medications, due to evidence of its ineffectiveness as a nasal decongestant.
The proposal follows an FDA advisory committee's conclusion that oral phenylephrine does not work, with the public comment period open until May 7, 2025.

FDA Proposes Ban on Oral Phenylephrine for Cold Relief Due to Ineffectiveness

The FDA is moving to remove oral phenylephrine from the list of approved over-the-counter ingredients due to its lack of efficacy as a nasal decongestant.
Scientific reviews indicate that less than 1% of orally administered phenylephrine is absorbed into the bloodstream, rendering it ineffective.

FDA Proposes Removal of Oral Phenylephrine as Ineffective Nasal Decongestant

The FDA is proposing to remove oral phenylephrine from over-the-counter (OTC) cold medications, deeming it ineffective as a nasal decongestant.
This decision follows a review of available data, including historical data and recent studies, which showed phenylephrine was no more effective than a placebo.

FDA Proposes Removal of Oral Phenylephrine as Ineffective Decongestant

The FDA has proposed removing oral phenylephrine from the list of approved over-the-counter decongestants due to its lack of efficacy in relieving nasal congestion.
This decision follows a review of available data and advice from an advisory committee, which concluded that oral phenylephrine is not effective as a nasal decongestant.

FDA Proposes Ban on Oral Phenylephrine in Over-the-Counter Decongestants

The FDA is seeking to ban oral phenylephrine in OTC nasal decongestants due to research indicating its ineffectiveness as a pill or syrup.
The proposal follows a review of data, including a September 2023 advisory committee conclusion, questioning phenylephrine's efficacy as a decongestant.

FDA Proposes Removing Oral Phenylephrine from OTC Nasal Decongestants

The FDA is proposing to remove oral phenylephrine as an active ingredient in over-the-counter (OTC) monograph drug products for temporary nasal congestion relief.
This decision follows an FDA review that concluded oral phenylephrine is ineffective in relieving nasal congestion at recommended doses.

Reference News

[1]
FDA Proposes Ban on Over-the-Counter Decongestant - Nevada Globe
thenevadaglobe.com · Nov 9, 2024

FDA proposes removing oral phenylephrine from OTC cold meds due to lack of efficacy as a nasal decongestant, not safety ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy